Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ibalizumab + chidamide
- Development stage
- Phase 1
- Lead developer
- Zhejiang University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Ibalizumab + chidamide is an investigational combination regimen being evaluated for the treatment of HIV-1 infection, specifically targeting the reduction of the latent HIV reservoir. This therapeutic approach utilizes a 'shock and kill' strategy: chidamide (also known as tucidinostat) acts as a selective histone deacetylase (HDAC) inhibitor and latency reversal agent to reactivate ('shock') latent HIV-1 from cellular reservoirs, while ibalizumab, a humanized IgG4 monoclonal antibody, acts as a post-attachment inhibitor by binding to domain 2 of the CD4 receptor to block viral entry and facilitate the clearance ('kill') of reactivated cells. The combination is currently being studied in a Phase 1 dose-escalation clinical trial led by the First Affiliated Hospital of Zhejiang University in adults living with HIV who are on stable antiretroviral therapy (ART).
- Other names
- ibalizumab + tucidinostat
02
Targets
CD4 (T lymphocyte surface antigen)HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC11 (Histone Deacetylase 11)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)HDAC8 (Histone Deacetylase 8)
Beyond the preview
Go deeper on ibalizumab + chidamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ibalizumab + chidamide.